Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 0.50 |
| ▸ | PGR | P06401 | 5/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754374 | 1.00 | NR3C1 (0.50) | NR3C1PGRAR | |
| SCHEMBL3138916 | 1.00 | NR3C1 (0.50) | NR3C1PGRAR | |
| SCHEMBL753547 | 0.94 | NR3C1 (0.47) | NR3C1PGRAR | |
| SCHEMBL753984 | 0.92 | NR3C1 (0.47) | NR3C1PGRAR | |
| SCHEMBL751376 | 0.92 | NR3C1 (0.47) | NR3C1PGRAR | |
| SCHEMBL754021 | 0.91 | NR3C1 (0.48) | NR3C1PGRAR | |
| SCHEMBL752126 | 0.91 | NR3C1 (0.57) | NR3C1PGRAR | |
| SCHEMBL764264 | 0.90 | NR3C1 (0.51) | NR3C1PGRAR | |
| SCHEMBL753652 | 0.90 | NR3C1 (0.47) | NR3C1PGRAR | |
| SCHEMBL750729 | 0.90 | NR3C1 (0.49) | NR3C1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222247-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222247-B2 | Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2078015-B1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1 AND/OR NF-KAPPAB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-07 | — | — | US | disclosed |
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004219-A1 | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF | NR3C1, NFRKB, RELA | NR3C1 1/4885PGR 2359/4885AR 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.